Company intelligence / Profile preview

Polaris Pharmaceuticals

San Diego, California, United Statespolarispharma.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 3

Overview

Pegargiminase (ADI‑PEG 20) is a novel biologic that deprives certain cancers of arginine and has been tested in over twenty clinical trials globally for various solid and hematologic tumors. It has received orphan drug status for several indications and is being evaluated both as monotherapy and in combination with chemotherapy or immuno-oncology agents. The company has established multiple regional licensing/distribution agreements to commercialize its lead asset internationally.

Therapeutic areas: OncologyHematology
Modalities: Protein therapeutics/biologics (notably pegylated enzymes such as Pegargiminase/ADI‑PEG 20)Small molecules (in early research programs)
Industry: Biotech

Drug pipeline

2 assets

Pegargiminase

1 more asset in the full pipeline.

Request access →

Partnerships

Er-Kim Pharmaceuticals – exclusive distribution agreement for Pegargiminase across EMEA marketsTabuk Pharmaceutical Manufacturing Company – exclusive licensing agreement for Saudi Arabia & GCC regionMD Anderson Cancer Center – strategic collaboration on immunotherapy platform and biomarker studies

Beyond the preview

Go deeper on Polaris Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polaris Pharmaceuticals.

Explore the full profile